Linkage Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Linkage Biosciences - overview
Established
2004
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Linkage Biosciences specializes in advanced genetics solutions, providing innovative PCR typing kits designed for rapid and efficient genotyping in laboratories. Founded in 2004 and headquartered in San Francisco, US, Linkage Biosciences focuses on developing PCR typing technology. The company has successfully completed 8 deals, with its most recent funding round occurring in May 2013 when it raised USD 2. 00 mn in a GROWTH round, led by Fisher Capital along with Big Sky Partners and Greenhouse Capital Partners.
No significant changes in business strategy have been reported. The background of the founder is not specified, and no subsidiaries or parent companies are mentioned. Linkage Biosciences offers the LinkSēq PCR Typing Kits, which enable rapid genotyping with a streamlined workflow that minimizes contamination risks. These kits facilitate high-throughput processing of samples, allowing amplification in just 90 minutes.
They are essential for areas such as HLA and KIR genotyping, as well as blood genotyping for RH, ABO, and HPA. The main customers include biopharmaceutical companies, transplant laboratories, and research institutions spread across North America, Europe, and Asia. Linkage Biosciences generates revenue through direct sales of its LinkSēq PCR Typing Kits and related products to laboratories and research institutions. The business model includes B2B transactions, where customers order kits based on their genotyping needs.
Revenue streams consist of both one-time kit purchases and ongoing accessory sales, such as the LinkSēq Wipe Test, which complements their core products. The pricing is tailored to fulfill specific genotyping requirements of institutions. Linkage Biosciences plans to leverage the USD 2. 00 mn raised in May 2013 to enhance its product offerings and expand into new markets.
The company is focusing on designing innovative products that cater to evolving needs in genetic analysis, with a timeline for new product launches expected in the next 12 to 18 months. Additionally, Linkage aims to penetrate new geographic regions, particularly in Europe and Asia by 2015, to broaden its market presence.
Current Investors
Big Sky Partners, Greenhouse Capital Partners, Fisher Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.linkagebio.com
Company Stage
Growth Stage/Expansion
Total Amount Raised
Subscriber access only
Linkage Biosciences - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.